January 16, 2020
1 min read
Save

Glaukos leverages acquisitions to enter new ophthalmology spaces

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

With recent acquisitions, Glaukos now has multiple products in development that expand its reach outside of the glaucoma space and into more comprehensive ophthalmology, CEO Tom Burns said at the J.P. Morgan Healthcare Conference.

“Our mission at Glaukos from our inception has been to transform glaucoma therapy, but our vision has always been broader and more inspirational,” Burns said. “Over the last several years, we’ve been building the foundation to create the next formidable comprehensive eye care company in ophthalmology.”

While Glaukos’ glaucoma products are doing well, the company is now reaching into cornea and retinal therapies to expand its portfolio.

Its acquisition of Avedro brings a cross-linking procedure that addresses keratoconus and is expected to expand into an epi-on cross-linking procedure, as well as possible refractive uses.

“iLink is the proprietary name of our cross-linking procedure, and we expect to command a presence and make it the standard of care in keratoconus,” Burns said. “And we’re going to modulate the UVA beam to be able to reshape the cornea in fashions we see fit to treat refractive disorders in the future.”

In addition, Glaukos is in-licensing the Intratus topical therapy for dry eye disease.

“In corneal health, we already have four distinct programs that are treating three disease states and refractive disorders, and we expect this to give us a bountiful growth proposition through the 2020s,” Burns said.

The acquisition of Dose Medical further expands Glaukos’ reach with an entry into the retina market.

Microinvasive, bioerodible drug delivery implants are currently being tested by the company for the treatment of retinal diseases.

“A company that’s had an obsessive focus on transforming glaucoma therapy has now transformed itself into a unique, formidable, comprehensive eye care company,” Burns said.

Reference:

Burns T. Glaukos. Presented at the J.P. Morgan Healthcare Conference; Jan 13-16, 2020; San Francisco.

Disclosure: Burns reports he is president and CEO of Glaukos.